Research Only Cognitive & Nootropic

NPAS3 Research Peptide

also known as: Neuronal PAS domain protein 3 fragment

A research-only peptide derived from the NPAS3 (neuronal PAS domain protein 3) basic helix-loop-helix PAS transcription factor. NPAS3 has been linked to schizophrenia and cognitive phenotypes in human genetic studies, but the peptide itself has no clinical development. No human trials, no established dosing, and no substantiated therapeutic use.

A short peptide fragment corresponding to a sequence within the bHLH-PAS transcription factor NPAS3. NPAS3 knockout in mice produces schizophrenia-like behavioral abnormalities and reduced adult hippocampal neurogenesis, and NPAS3 loss-of-function has been reported in rare human schizophrenia and intellectual disability pedigrees. Peptide fragments of NPAS3 have been examined in a small research literature primarily for their DNA-binding or protein-protein interaction properties. No therapeutic development; research-only.

Mechanism of action

NPAS3 is a member of the bHLH-PAS transcription factor family that dimerizes with ARNT (HIF-1β) and binds E-box elements to regulate genes involved in neurogenesis, circadian biology, and xenobiotic response. NPAS3-deficient mice show reduced adult hippocampal neurogenesis, altered social and prepulse inhibition behaviors, and changes in FGF signaling. Short NPAS3-derived peptides have primarily been used as research tools for studying bHLH-PAS dimerization or as epitopes for antibody generation, not as functional therapeutic mimetics.

Primary uses

Transcription-factor research (in vitro)
Schizophrenia and neurodevelopmental genetics research (preclinical)

Typical dosing

Not established

⚠ No human dosing has ever been established. Any human use would be entirely experimental and unsupported.

Regulatory status

Not FDA-approved. No registered clinical trials. No sponsoring developer. Listed in some grey-market research-peptide catalogs as a nootropic candidate; any such characterization is not supported by clinical evidence.

References

[pubmed] Kamnasaran D, et al. "Disruption of the neuronal PAS3 gene in a family affected with schizophrenia." J Med Genet, 2003;40:325-332.
[pubmed] Pieper AA, et al. "The neuronal PAS domain protein 3 transcription factor controls FGF-mediated adult hippocampal neurogenesis in mice." Proc Natl Acad Sci USA, 2005;102:14052-14057.

Related peptides

BRN2 (POU3F2) Research Peptide

A research-only peptide derived from the POU3F2 (BRN2) neural transcription factor; mechanistic and phenotypic evidence is limited almost entirely to in vitro and lineage-specification studies. No human therapeutic development, no clinical trials, no established dosing, and no commercial availability through regulated channels.

P21

A CNTF-derived research peptide (Institute for Basic Research, New York) that crosses the blood-brain barrier and stimulates hippocampal neurogenesis in rodent models of Alzheimer disease, Down syndrome, and aging. Not FDA-approved; not commercially marketed; research-only with no human trials to date.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.